Login to Your Account

Peptidream pull persuades Bayer to ink $1.11B licensing deal

By Michael Fitzhugh
Staff Writer

Monday, November 20, 2017

Bayer AG is betting up to $1.11 billion (¥124.5 billion) that Peptidream Inc.'s popular therapeutic peptide discovery platform will help it discover novel lead structures in areas such as cancer and cardiology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription